Davis's Drug Guide
lazertinib
General
High Alert Medication: This medication bears a heightened risk of causing significant patient harm when it is used in error.
Genetic Implications:
Pronunciation:
laz-er-ti-nib
Trade Name(s)
- Lazcluze
Ther. Class.
Pharm. Class.
kinase inhibitors
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Vallerand, April Hazard., and Cynthia A. Sanoski. "Lazertinib." Davis's Drug Guide, 20th ed., F.A. Davis Company, 2026. Medicine Central, im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580134/all/lazertinib.
Vallerand AHA, Sanoski CAC. Lazertinib. Davis's Drug Guide. F.A. Davis Company; 2026. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580134/all/lazertinib. Accessed June 25, 2026.
Vallerand, A. H., & Sanoski, C. A. (2026). Lazertinib. In Davis's Drug Guide (20th ed.). F.A. Davis Company. https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580134/all/lazertinib
Vallerand AHA, Sanoski CAC. Lazertinib [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2026. [cited 2026 June 25]. Available from: https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580134/all/lazertinib.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - lazertinib
ID - 3580134
A1 - Sanoski,Cynthia A,
AU - Vallerand,April Hazard,
BT - Davis's Drug Guide
UR - https://im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/3580134/all/lazertinib
PB - F.A. Davis Company
ET - 20
DB - Medicine Central
DP - Unbound Medicine
ER -
